Archives
-
β-Pseudouridine: RNA Workflow & Applications
2026-09-22
β-Pseudouridine is a C-glycoside isomer of uridine for investigating RNA structure, translational fidelity, and stress-response biology. This guide separates free-nucleoside assay use from triphosphate-dependent RNA synthesis and translates recent self-amplifying RNA findings into practical experimental choices.
-
p21 mRNA-LNP Delivery for Bladder Cancer
2026-09-22
The reference study develops an intravesical lipid nanoparticle platform for delivering chemically modified p21 mRNA to bladder tumors, addressing the delivery limitations of systemic mRNA therapy. Its preclinical data connect localized p21 restoration with cell-cycle suppression, DNA-damage signaling, apoptosis, tumor growth control, and limited systemic exposure.
-
Trilaurin for Oral Peptide Delivery
2026-09-21
Trilaurin, or Glycerol Tridodecanoate, is a defined C12 triacylglycerol that connects solid lipid microparticle design with enzyme-assisted synthesis. This practical guide covers formulation workflows, digestion-based assays, biocatalytic benchmarking, and troubleshooting for peptide, protein, and lipid research.
-
Diminazene Aceturate: Designing Better Assays
2026-09-21
Diminazene Aceturate is both a trypanocidal research compound and an emerging ACE2 activation probe. This guide presents an assay-design framework for separating antiparasitic activity from mitochondrial and cardiac pathway effects.
-
Cy5-UTP for RNA Imaging: From Probe to Proof
2026-09-20
Cy5-UTP enables direct fluorescent RNA labeling during T7 in vitro transcription. This guide connects Cyanine 5-uridine triphosphate chemistry with spatial assay design, RNA quality controls, FISH, and emerging mRNA-delivery research.
-
Affinity-Purified Goat Anti-Rabbit IgG (H+L)
2026-09-19
Build reproducible Western blot, ELISA, and IHC workflows around an affinity-purified HRP secondary that converts rabbit primary-antibody binding into measurable enzymatic signal. The workflow also shows how PSMD13-focused liver cancer studies can guide tissue controls, paired-sample analysis, and assay optimization.
-
Z-VEID-FMK: Caspase-6 Inhibitor Guide
2026-09-18
Z-VEID-FMK is a cell-permeable, irreversible caspase-6 inhibitor for apoptosis assays and caspase activity measurement. Product specifications and a 2025 rat inflammatory-pain study support its use as a mechanistic research tool, while model transfer and target selectivity require experimental verification.
-
Biodegradable Polyesters for VEGF mRNA Delivery
2026-09-18
The reference study develops three-armed biodegradable polyesters that combine mRNA-complexing cationic behavior with ester-based degradability and intrinsic redox-related activity. In critical limb ischemia, arginine-functionalized particles improved VEGF mRNA delivery while scavenging reactive oxygen species and releasing nitric oxide, providing a multifunctional rationale for therapeutic angiogenesis.
-
8-Chloroadenosine in RNA Stability Research
2026-09-17
8-Chloroadenosine offers a practical way to examine how transcriptional suppression changes RNA stability in cancer models. This article connects its use as a nucleoside analog inhibitor with the RP3-340N1.2–IL-6–ZC3H12A axis while emphasizing rigorous assay interpretation.
-
EZ Cap™ Mouse CD252(OX40L) mRNA Assays
2026-09-17
EZ Cap™ Mouse CD252(OX40L) mRNA (m1Ψ, HA tag) enables controlled investigation of OX40L-mediated immune co-stimulation. This guide presents a layered assay framework that separates mRNA expression, ligand display, receptor engagement, and functional T-cell outcomes.
-
RNA Stability and Translation with HyperScribe™
2026-09-16
Early embryonic development illustrates why RNA quality is a biological variable, not merely a manufacturing detail. A recent HFM1 study linked defective mRNA splicing and failed nuclear localization to disrupted zygotic genome activation and embryonic arrest, while wild-type HFM1 mRNA rescued defects in a mouse embryo model. This article translates that mechanistic insight into practical guidance for researchers engineering RNA for micro-injection, transfection, and gene-expression studies. It examines how enzymatic polyadenylation with E. coli Poly (A) Polymerase can support mRNA stability enhancement and translation efficiency improvement, explains where the HyperScribe™ Poly (A) Tailing Kit fits within an in vitro transcription workflow, and outlines the validation controls required before making translational claims.
-
HyperScribe All in One mRNA Synthesis Kit Guide
2026-09-16
Build ARCA-capped, polyadenylated mRNA in a streamlined T7 transcription workflow for translation, RNA interference, and vaccine research. The integrated capping, DNase treatment, and poly(A) tailing design helps connect reproducible bench synthesis with emerging spleen-targeted neoantigen vaccine studies.
-
UTP and Epigenetic Control of RNA Identity
2026-09-15
TRIM66-mediated repression provides a compelling model for how cells convert a probabilistic transcriptional state into stable receptor identity. This thought-leadership article connects that mechanism to practical RNA workflow design, showing how a well-controlled UTP Solution can support translational assays without overstating what the reagent itself proves.
-
Carbohydrate-Decorated Nanoparticles Target Macrophages
2026-09-15
The reference study developed biodegradable PLGA- and PLGA-PEG-based nanoparticles decorated with mannose, galactose, dextran, or mixed carbohydrates to improve macrophage gene delivery. Its results show that carbohydrate identity and surface presentation influence nanoparticle uptake and reporter-mRNA transfection, with mannose and dextran producing particularly useful targeting profiles in Raw 264.7 macrophages.
-
FLCN Mutations and mRNA Rescue in BHD Syndrome
2026-09-14
A recent family-based study identified a novel pathogenic FLCN nonsense variant and supplied genetic and functional evidence that the previously uncertain p.W376R variant is pathogenic. In HEK293T cells, synthetic FLCN mRNA restored FLCN expression and reduced abnormal mTORC1 activation, providing an early in vitro rationale for mRNA-based protein replacement in Birt-Hogg-Dubé syndrome.